Recurrence of Nonviral Diseases

Clinics in Liver Disease

Volumn 11, Issue 2, 2007, Pages 377-395

  Oo, Ye Htun ^a   Neuberger, James ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; ACETYLSALICYLIC ACID; AZATHIOPRINE; BENZIMIDAZOLE; CLOPIDOGREL; COLESTYRAMINE; CORTICOSTEROID; CYCLOSPORIN; DOXORUBICIN; GLITAZONE DERIVATIVE; HEMATIN; HYDROXYUREA; LEFLUNOMIDE; METFORMIN; MYCOPHENOLIC ACID; NALTREXONE; PREDNISOLONE; RAPAMYCIN; RIBAVIRIN; TACROLIMUS; URSODEOXYCHOLIC ACID; WARFARIN;

ALCOHOL LIVER DISEASE; ALLOGRAFT; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; BUDD CHIARI SYNDROME; CHEMOEMBOLIZATION; CHOLEDOCHOJEJUNOSTOMY; CHRONIC HEPATITIS; DRUG DOSE INCREASE; ERYTHROPOIETIC PROTOPORPHYRIA; GIANT CELL HEPATITIS; GRAFT FAILURE; GRAFT INFECTION; GRAFT REJECTION; GRAFT SURVIVAL; HEMOCHROMATOSIS; HUMAN; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FUNCTION; LIVER HYDATID CYST; LIVER TRANSPLANTATION; LOW DRUG DOSE; MORBIDITY; MORTALITY; NONALCOHOLIC FATTY LIVER; PATHOGENESIS; PLASMAPHERESIS; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; RADIOFREQUENCY ABLATION; RECURRENT DISEASE; RELAPSE; RETRANSPLANTATION; REVIEW; SARCOIDOSIS; SURVIVAL RATE; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME;

AUTOIMMUNE DISEASES; GRAFT SURVIVAL; HUMANS; LIVER DISEASES; LIVER TRANSPLANTATION; METABOLIC DISEASES; RECURRENCE;

EID: 34250864039     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2007.04.012     Document Type: Review

References (90)

1. Sanchez E.Q., Levy M.F., Goldstein R.M., et al. The changing clinical presentation of recurrent primary biliary cirrhosis after liver transplantation. Transplantation 76 (2003) 1583-1588
2. Haydon G.H., and Neuberger J. PBC: an infectious disease?. Gut 47 (2000) 586-588
3. Liermann Garcia R.F., Evangelista Garcia C., McMaster P., et al. Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center. Hepatology 33 (2001) 22-27
4. Balan V., Batts K.P., Porayko M.K., et al. Histological evidence for recurrence of primary biliary cirrhosis after liver transplantation. Hepatology 18 (1993) 1392-1398
5. Haagsma E.B. Clinical relevance of recurrence of primary biliary cirrhosis after liver transplantation. Eur J Gastroenterol Hepatol 11 (1999) 639-642
6. Levitsky J., Hart J., Cohen S.M., et al. The effect of immunosuppressive regimens on the recurrence of primary biliary cirrhosis after liver transplantation. Liver Transpl 9 (2003) 733-736
7. Neuberger J., Gunson B., Hubscher S., et al. Immunosuppression affects the rate of recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl 10 (2004) 488-491
8. Gautam M., Cheruvattath R., and Balan V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review. Liver Transpl 12 12 (2006) 1813-1824
9. Vierling J.M. Future treatment options in PBC. Semin Liver Dis 25 (2005) 347-363
10. Sylvestre P.B., Batts K.P., Burgart L.J., et al. Recurrence of primary biliary cirrhosis after liver transplantation: histologic estimate of incidence and natural history. Liver Transpl 9 (2003) 1086-1093
11. Renz J.F., and Ascher N.L. Liver transplantation for nonviral, nonmalignant diseases:problem of recurrence. World J Surg 26 (2002) 247-256
12. Manns M.P., and Bahr M.J. Recurrent autoimmune hepatitis after liver transplantation-when non-self becomes self. Hepatology 32 (2000) 868-870
13. Molmenti E.P., Netto G.J., Murray N.G., et al. Incidence and recurrence of autoimmune/alloimmune hepatitis in liver transplant recipients. Liver Transpl 8 (2002) 519-526
14. Wright H.L., Bou-Abboud C.F., Hassanein T., et al. Disease recurrence and rejection following liver transplantation for autoimmune chronic active liver disease. Transplantation 53 (1992) 136-139
15. Aguilera I., Wichmann I., Sousa J.M., et al. Antibodies against glutathione S-transferase T1 (GSTT1) in patients with de novo immune hepatitis following liver transplantation. Clin Exp Immunol 126 (2001) 535-539
16. Neuberger J., Portmann B., Calne R., et al. Recurrence of autoimmune chronic active hepatitis following orthotopic liver grafting. Transplantation 37 (1984) 363-365
17. Duclos-Vallee J.C., Sebagh M., Rifai K., et al. A 10 year follow up study of patients transplanted for autoimmune hepatitis: histological recurrence precedes clinical and biochemical recurrence. Gut 52 (2003) 893-897
18. Hubscher S.G. Recurrent autoimmune hepatitis after liver transplantation: diagnostic criteria, risk factors, and outcome. Liver Transpl 7 (2001) 285-291
19. Ayata G., Gordon F.D., Lewis W.D., et al. Liver transplantation for autoimmune hepatitis: a long-term pathologic study. Hepatology 32 (2000) 185-192
20. Ratziu V., Samuel D., Sebagh M., et al. Long-term follow-up after liver transplantation for autoimmune hepatitis: evidence of recurrence of primary disease. J Hepatol 30 (1999) 131-141
21. Bahar R.J., Yanni G.S., Martin M.G., et al. Orthotopic liver transplantation for autoimmune hepatitis and cryptogenic chronic hepatitis in children. Transplantation 72 (2001) 829-833
22. Milkiewicz P., Hubscher S.G., Skiba G., et al. Recurrence of autoimmune hepatitis after liver transplantation. Transplantation 68 (1999) 253-256
23. Hurtova M., Duclos-Vallee J.C., Johanet C., et al. Successful tacrolimus therapy for a severe recurrence of type 1 autoimmune hepatitis in a liver graft recipient. Liver Transpl 7 (2001) 556-558
24. Neuberger J. Transplantation for autoimmune hepatitis. Semin Liver Dis 22 (2002) 379-386
25. Narumi S., Roberts J.P., Emond J.C., et al. Liver transplantation for sclerosing cholangitis. Hepatology 22 (1995) 451-457
26. Goss J.A., Shackleton C.R., Farmer D.G., et al. Orthotopic liver transplantation for primary sclerosing cholangitis. A 12-year single center experience. Ann Surg 225 (1997) 472-481 [discussion: 481-73]
27. Graziadei I.W., Wiesner R.H., Marotta P.J., et al. Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. Hepatology 30 (1999) 1121-1127
28. Graziadei I.W., Wiesner R.H., Batts K.P., et al. Recurrence of primary sclerosing cholangitis following liver transplantation. Hepatology 29 (1999) 1050-1056
29. Harrison R.F., Davies M.H., Neuberger J.M., et al. Fibrous and obliterative cholangitis in liver allografts: evidence of recurrent primary sclerosing cholangitis?. Hepatology 20 (1994) 356-361
30. Vera A., Moledina S., Gunson B., et al. Risk factors for recurrence of primary sclerosing cholangitis of liver allograft. Lancet 360 (2002) 1943-1944
31. Kugelmas M., Spiegelman P., Osgood M.J., et al. Different immunosuppressive regimens and recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 9 (2003) 727-732
32. Kowdley K.V. Liver transplantation: an "in vivo" model for the pathophysiology of hemochromatosis?. Hepatology 39 (2004) 1495-1498
33. Pietrangelo A. Hereditary hemochromatosis-a new look at an old disease. N Engl J Med 350 (2004) 2383-2397
34. Ganz T. Hepcidin-a regulator of intestinal iron absorption and iron recycling by macrophages. Best Pract Res Clin Haematol 18 (2005) 171-182
35. Crawford D.H., Fletcher L.M., Hubscher S.G., et al. Patient and graft survival after liver transplantation for hereditary hemochromatosis: implications for pathogenesis. Hepatology 39 (2004) 1655-1662
36. Brandhagen D.J., Alvarez W., Therneau T.M., et al. Iron overload in cirrhosis-HFE genotypes and outcome after liver transplantation. Hepatology 31 (2000) 456-460
37. Kowdley K.V., Brandhagen D.J., Gish R.G., et al. Survival after liver transplantation in patients with hepatic iron overload: the national hemochromatosis transplant registry. Gastroenterology 129 (2005) 494-503
38. Srinivasan P., Rela M., Prachalias A., et al. Liver transplantation for Budd-Chiari syndrome. Transplantation 73 (2002) 973-977
39. Melear J.M., Goldstein R.M., Levy M.F., et al. Hematologic aspects of liver transplantation for Budd-Chiari syndrome with special reference to myeloproliferative disorders. Transplantation 74 (2002) 1090-1095
40. Mentha G., Giostra E., Majno P.E., et al. Liver transplantation for Budd-Chiari syndrome: a European study on 248 patients from 51 centres. J Hepatol 44 (2006) 520-528
41. Cengiz C., Rodriguez-Davalos M., deBoccardo G., et al. Recurrent hepatic sarcoidosis post-liver transplantation manifesting with severe hypercalcemia: a case report and review of the literature. Liver Transpl 11 (2005) 1611-1614
42. Lipson E.J., Fiel M.I., Florman S.S., et al. Patient and graft outcomes following liver transplantation for sarcoidosis. Clin Transplant 19 (2005) 487-491
43. Hunt J., Gordon F.D., Jenkins R.L., et al. Sarcoidosis with selective involvement of a second liver allograft: report of a case and review of the literature. Mod Pathol 12 (1999) 325-328
44. Meerman L., Haagsma E.B., Gouw A.S., et al. Long-term follow-up after liver transplantation for erythropoietic protoporphyria. Eur J Gastroenterol Hepatol 11 (1999) 431-438
45. Do K.D., Banner B.F., Katz E., et al. Benefits of chronic plasmapheresis and intravenous heme-albumin in erythropoietic protoporphyria after orthotopic liver transplantation. Transplantation 73 (2002) 469-472
46. Dellon E.S., Szczepiorkowski Z.M., Dzik W.H., et al. Treatment of recurrent allograft dysfunction with intravenous hematin after liver transplantation for erythropoietic protoporphyria. Transplantation 73 (2002) 911-915
47. Penn I. Hepatic transplantation for primary and metastatic cancers of the liver. Surgery 110 (1991) 726-734 [discussion: 734-25]
48. Mazzaferro V., Regalia E., Doci R., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334 (1996) 693-699
49. Ringe B., Pichlmayr R., Wittekind C., et al. Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients. World J Surg 15 (1991) 270-285
50. Roayaie S., Schwartz J.D., Sung M.W., et al. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl 10 (2004) 534-540
51. Marsh J.W., Dvorchik I., Subotin M., et al. The prediction of risk of recurrence and time to recurrence of hepatocellular carcinoma after orthotopic liver transplantation: a pilot study. Hepatology 26 (1997) 444-450
52. Schwartz M., Roayaie S., and Llovet J. How should patients with hepatocellular carcinoma recurrence after liver transplantation be treated?. J Hepatol 43 (2005) 584-589
53. Regalia E., Fassati L.R., Valente U., et al. Pattern and management of recurrent hepatocellular carcinoma after liver transplantation. J Hepatobiliary Pancreat Surg 5 (1998) 29-34
54. Llovet J.M., and Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37 (2003) 429-442
55. Leung T.W., Tang A.M., Zee B., et al. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. Cancer 94 (2002) 421-427
56. Fung J., and Marsh W. The quandary over liver transplantation for hepatocellular carcinoma: the greater sin?. Liver Transpl 8 (2002) 775-777
57. Starzl T.E., Van Thiel D., Tzakis A.G., et al. Orthotopic liver transplantation for alcoholic cirrhosis. JAMA 260 (1988) 2542-2544
58. Pereira S.P., and Williams R. Liver transplantation for alcoholic liver disease at King's College Hospital: survival and quality of life. Liver Transpl Surg 3 (1997) 245-250
59. Berlakovich G.A., Windhager T., Freundorfer E., et al. Carbohydrate deficient transferrin for detection of alcohol relapse after orthotopic liver transplantation for alcoholic cirrhosis. Transplantation 67 (1999) 1231-1235
60. Berlakovich G.A., Steininger R., Herbst F., et al. Efficacy of liver transplantation for alcoholic cirrhosis with respect to recidivism and compliance. Transplantation 58 (1994) 560-565
61. Bellamy C.O., DiMartini A.M., Ruppert K., et al. Liver transplantation for alcoholic cirrhosis: long term follow-up and impact of disease recurrence. Transplantation 72 (2001) 619-626
62. Cuadrado A., Fabrega E., Casafont F., et al. Alcohol recidivism impairs long-term patient survival after orthotopic liver transplantation for alcoholic liver disease. Liver Transpl 11 (2005) 420-426
63. Neuberger J., Schulz K.H., Day C., et al. Transplantation for alcoholic liver disease. J Hepatol 36 (2002) 130-137
64. Pageaux G.P., Bismuth M., Perney P., et al. Alcohol relapse after liver transplantation for alcoholic liver disease: does it matter?. J Hepatol 38 (2003) 629-634
65. Jauhar S., Talwalkar J.A., Schneekloth T., et al. Analysis of factors that predict alcohol relapse following liver transplantation. Liver Transpl 10 (2004) 408-411
66. Gish R.G., Lee A., Brooks L., et al. Long-term follow-up of patients diagnosed with alcohol dependence or alcohol abuse who were evaluated for liver transplantation. Liver Transpl 7 (2001) 581-587
67. Webb K., and Neuberger J. Transplantation for alcoholic liver disease. BMJ 329 (2004) 63-64
68. DiMartini A., Weinrieb R., and Fireman M. Liver transplantation in patients with alcohol and other substance use disorders. Psychiatr Clin North Am 25 (2002) 195-209
69. Angelico F., Del Ben M., Francioso S., et al. Recurrence of insulin resistant metabolic syndrome following liver transplantation. Eur J Gastroenterol Hepatol 15 (2003) 99-102
70. Burke A., and Lucey M.R. Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and orthotopic liver transplantation. Am J Transplant 4 (2004) 686-693
71. Hagen M., Hjelmesaeth J., Jenssen T., et al. A 6-year prospective study on new onset diabetes mellitus, insulin release and insulin sensitivity in renal transplant recipients. Nephrol Dial Transplant 18 (2003) 2154-2159
72. Contos M.J., Cales W., Sterling R.K., et al. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl 7 (2001) 363-373
73. Marchetti P., and Navalesi R. The metabolic effects of cyclosporin and tacrolimus. J Endocrinol Invest 23 (2000) 482-490
74. Burke III G.W., Cirocco R., Hensley G., et al. Liver transplantation for cirrhosis following jejuno-ileal bypass-regional cytokine differences associated with pathological changes in the transplant liver. Transplantation 54 (1992) 374-377
75. Kim W.R., Poterucha J.J., Porayko M.K., et al. Recurrence of nonalcoholic steatohepatitis following liver transplantation. Transplantation 62 (1996) 1802-1805
76. Ayata G., Gordon F.D., Lewis W.D., et al. Cryptogenic cirrhosis: clinicopathologic findings at and after liver transplantation. Hum Pathol 33 (2002) 1098-1104
77. Saab S., Cho D., Lassman R.C., et al. Recurrent non-alcoholic steatohepatitis in a living related liver transplant recipient. J Hepatol 42 (2005) 148-149
78. Poordad F., Gish R., Wakil A., et al. De novo non-alcoholic fatty liver disease following orthotopic liver transplantation. Am J Transplant 3 (2003) 1413-1417
79. Duchini A., and Brunson M.E. Roux-en-Y gastric bypass for recurrent nonalcoholic steatohepatitis in liver transplant recipients with morbid obesity. Transplantation 72 (2001) 156-159
80. Caldwell S.H., Oelsner D.H., Iezzoni J.C., et al. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 29 (1999) 664-669
81. Poonawala A., Nair S.P., and Thuluvath P.J. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology 32 (2000) 689-692
82. Berg T., Neuhaus R., Klein R., et al. Distinct enzyme profiles in patients with cryptogenic cirrhosis reflect heterogeneous causes with different outcomes after liver transplantation (OLT): a long-term documentation before and after OLT. Transplantation 74 (2002) 792-798
83. Ong J., Younossi Z.M., Reddy V., et al. Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. Liver Transpl 7 (2001) 797-801
84. Bresson-Hadni S., Koch S., Beurton I., et al. Primary disease recurrence after liver transplantation for alveolar echinococcosis: long-term evaluation in 15 patients. Hepatology 30 (1999) 857-864
85. Phillips M.J., Blendis L.M., Poucell S., et al. Syncytial giant-cell hepatitis. Sporadic hepatitis with distinctive pathological features, a severe clinical course, and paramyxoviral features. N Engl J Med 324 (1991) 455-460
86. Pappo O., Yunis E., Jordan J.A., et al. Recurrent and de novo giant cell hepatitis after orthotopic liver transplantation. Am J Surg Pathol 18 (1994) 804-813
87. Lerut J.P., Claeys N., Ciccarelli O., et al. Recurrent postinfantile syncytial giant cell hepatitis after orthotopic liver transplantation. Transpl Int 11 (1998) 320-322
88. Nair S., Baisden B., Boitnott J., et al. Recurrent, progressive giant cell hepatitis in two consecutive liver allografts in a middle-aged woman. J Clin Gastroenterol 32 (2001) 454-456
89. Durand F., Degott C., Sauvanet A., et al. Subfulminant syncytial giant cell hepatitis: recurrence after liver transplantation treated with ribavirin. J Hepatol 26 (1997) 722-726
90. Hassoun Z., N'Guyen B., Cote J., et al. A case of giant cell hepatitis recurring after liver transplantation and treated with ribavirin. Can J Gastroenterol 14 (2000) 729-731